INTRODUCTION
Inflammation and remodelling are orchestrated responses ultimately addressed to promote tissue repair after organ injury. However, maintenance of the injury results in the activation of a profibrogenic cascade of events in chronic liver disease that finally leads to cirrhosis. Cirrhosis is a major determinant of morbidity and mortality and predisposes to hepatic failure and primary liver cancer. Therefore, halting the progression of fibrosis to cirrhosis has largely been considered as a foremost goal in patients with liver disease (Friedman, 2010) . Inflammation is an early event in the history of the disease. It occurs before the onset of significant clinical manifestations and becomes chronic during the evolution of the illness, particularly in patients with viral infection (Marra, 1999) . This dynamic inflammatory state has been associated with liver fibrogenesis and fibrosis in experimental cirrhosis (Muñoz-Luque et al., 2008) . In addition, many inflammatory mediators have direct angiogenic activities and in turn, angiogenesis contributes to the perpetuation and the amplification of the inflammatory state by promoting the recruitment of inflammatory cells in the neovasculature (Tugues et al., 2007; Morales-Ruiz and Jiménez, 2005) . Therefore, inflammation, fibrogenesis and angiogenesis are three closely related phenomena in chronic liver disease.
Under this scenario, suitable targets for antifibroproliferative therapies should include molecules which are critical in fibrosis progression and also possess inflammatory and/or angiogenic-related properties. In this regard two recently characterized endogenous hepatic systems are attracting increasing attention, namely the hepatic endocannabinoid and apelin systems.
Endocannabinoids are lipid-related molecules participating in a wide range of
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J P E T # 1 8 8 0 7 8 6 physiological functions including neuroprotection, pain and motor function, energy balance and food intake, cardiovascular homeostasis, immune and inflammatory responses and cell proliferation (Pacher et al., 2006; Tam et al., 2011; Reichenbach et al., 2010) . These effects are mediated by interaction with two different types of receptors, the CB1 and CB2 receptors. Interestingly, the CB1 receptor in the liver has been shown to mediate profibrogenic effects (Teixera-Clerc et al., 2006) and has also been implicated in the pathogenesis of alcoholic and non alcoholic liver disease (Jeong et al., 2006; Hézode et al., 2008) . On the other hand, CB2 receptor agonism shows opposite antifibrogenic and anti-inflammatory effects in hepatic and non-hepatic tissue (Muñoz-Luque et al., 2008; Akhmetshina et al., 2009 ) and protects against liver ischemiareperfusion injury (Horváth et al., 2011) . Previous studies by our laboratory have demonstrated that the proangiogenic peptide, apelin (AP) is up-regulated in HSCs of patients with cirrhosis (Melgar-Lesmes et al., 2010) . Furthermore, this peptide behaves as a paracrine mediator of fibrogenesis-related gene induction in human HSCs (Melgar-Lesmes et al., 2010) , and apelin receptor (APJ) blockade has shown to be effective in reducing hepatic fibrosis and angiogenesis in rats with cirrhosis (Principe et al., 2008) . Recent studies have also suggested that the apelin system is involved in inflammation and in endothelial cell proliferation (Masri et al., 2004; Daviaud et al., 2006) .
In the present investigation we sought to examine new therapeutic strategies to prevent the progression of fibrosis in injured livers of rats chronically receiving increasing doses of CCl 4 . We assessed the changes in messenger expression of a panel of genes involved in inflammation and/or tissue remodeling and the anti -fibrogenic, -angiogenic and -inflammatory by CCl 4 inhalation as described previously (Clària and Jiménez, 1999) . Briefly, animals were exposed to to a CCl 4 vapor atmosphere twice a week, starting at 0.5 minutes per exposure. The duration of the exposure was increased by 1 minute after every three sessions until it reached 5 minutes, which was used until the end of the investigation. Rats with fibrosis were studied 13 weeks after starting the fibrosis induction protocol. Control rats were studied following a similar period of phenobarbital administration. The study was performed according to the criteria of the Investigation and Ethics Committees of the Hospital Clínic Universitari.
Selective activation of CB2 receptors in fibrotic rats. The hemodynamic and gene expression effects of CB2 receptor activation were assessed in 20 rats with fibrosis. Ten animals were randomly assigned to a daily subcutaneous injection of a specific CB2 agonist, AM1241 ((R,S)-3-(2-
1mg/kg/day bwt) (Malan et al., 2001 ). In parallel, 10 rats received a solution of ethanol:cremophor-ELP:saline (1:1:18) as vehicle. AM1241 or vehicle was administered from the 9 th to the 13 th week after starting the fibrosis induction protocol.
This article has not been copyedited and formatted. The final version may differ from this version. ]-Apelin-13 sequence: Gln-Arg-Pro-Arg-Leu-Ser-His-Lys-Gly-ProMet-Pro-Ala) at a dose of 75 µg/kg/day bwt (Phoenix Pharmaceuticals, Burlingame, California, USA) and 10 rats received 1ml/kg/day of saline solution as vehicle. F13A or vehicle was administered from the 9 th to the 13 th week after starting the fibrosis induction protocol.
Hemodynamic studies. Rats with fibrosis and control rats were anesthetized with Inactin (50 mg/kg bwt; Sigma-Aldrich Chemie Gmbh) and prepared with a polyvinyl-50 catheter in the left femoral artery. The animals were prepared for measurements of hemodynamic parameters as described (Ros et al., 2005) . Hemodynamic parameters were allowed to equilibrate for 30
minutes and values of mean arterial pressure (MAP), portal pressure (PP) and heart rate (HR) were recorded. Splanchnic perfusion pressure (SPP) was defined as MAP-PP. At the end of the study, the animals were exsanguinated and a blood sample (6-9 ml) was taken to measure standard parameters of hepatic and renal function. caspase-3, and blocked with 5% non fat milk for PDGFRβ and 1% BSA for TIMP1 and caspase-3 in TTBS buffer at room temperature for 2h. All membranes were stained with Ponceau S Red as a control for protein loading, and were then incubated overnight at 4ºC with rabbit polyclonal anti-PDGFRβ
(1:1000; Cell Signaling, Technology, Beverly, MA), anti-TIMP1 (1:1000; Abcam, Cambridge, UK) and anti-activated caspase-3 (1:300 dilution; Abcam) for 24h, 24h or 48h, respectively. The bands were visualized by chemiluminescence (Lumi-Light Western blotting substrate, Roche Diagnostics).
Immunodetection of CD68 and von Willebrand Factor (vWF).
Liver sections from cirrhotic rats underwent microwave antigen retrieval to unmask antigens hidden by cross linkage occurring during tissue fixation. Endogenous peroxidase activity was blocked by hydrogen peroxide pretreatment for 10 minutes and with 5% goat serum for 45 minutes. The sections were then stained with mouse anti-CD68 (1:150, Abd Serotec, Oxford, UK) or with rabbit anti-vWF (1:500, Dako, Glostrup, DK) and incubated one hour at room temperature or overnight at 4ºC, respectively. The LSAB® 2 System-HRP (Dako) was used for antigen detection and antigen visualization was achieved with streptavidin peroxidase and counterstained with hematoxylin. Effect of CB2 receptor activation and APJ blockade on liver fibrosis in fibrotic rats. Sirius red, a dye that selectively binds collagen proteins, was used to stain the collagen fibrils in the liver of CCl 4 -treated rats (Jiménez et al., 1985) . As shown in Figure 1 both groups of rats had remarkable fibrosis showing initial stages of the characteristic pattern of perivenular and periportal deposition of connecting tissue with development of thin portal-to-portal septa and slight evidence of architectural distortion resulting in micronodular fibrosis.
However, biopsies obtained from fibrotic rats receiving AM1241 and from fibrotic rats receiving F13A displayed thinner septa and more preserved hepatic Whereas the experimental design of these studies focused on fibrosis regression, here we assessed whether CB2 agonism is able to prevent fibrosis by CB2 agonism has been the major rationale to propose this mechanism as an antifibrogenic therapy. However, previous studies showed that pharmacological activation of the CB2 receptor signaling pathway may also induce inflammation in adipose tissue but not in the liver (Deveaux et al., 2009) . In agreement with these findings, treatment with the CB2 agonist in addition to stopping fibrosis progression and angiogenesis, was also associated with decreased serum levels of AST and ALT and reduced inflammatory infiltrate. An interesting finding of this study was that in contrast to what we had previously found in cirrhotic rats (Muñoz-Luque et al, 2008) , administration of AM1241 inhibited apoptosis in fibrotic animals. Although we do not have any experimental data to explain this phenomenon, we believe that it is likely related to the different degrees of active fibrogenesis between the two groups of CCl 4 -treated animals.
In fact, in the former study the rats had fully established cirrhosis and the active fibrogenesis was much lower than in the animals of the current investigation that were within the initial phases of fibrosis development (Iredale, 2007 , Gressner et al., 2007 . There are a number of potential mechanisms mediating the effects of CB2 receptor stimulation on hepatic fibrosis. They are likely The current investigation indicates that in addition to favoring cell viability, CB2 stimulation or APJ blockade also interferes with the production of profibrogenic mediators produced during chronic liver injury and the concomitant tissue repair. In this regard it is noteworthy the inhibitory effect on PDGF signaling shared by both AM1241 and F13A considering that PDGF is the most potent pro-proliferative cytokine for HSCs (Pinzani et al., 1989; Friedman, 2008) .
Pharmacological stimulation of the CB2 receptor or inhibition of AP activity also appears to affect the synthesis of molecules implicated in ECM remodeling. The net deposition of scar tissue depends on the balance between synthesis and degradation. The latter reflects the relative activity of MMPs and their inhibitor TIMPs, which are mainly produced by HSCs and other inflammatory cells (Friedman, 2008; Iredale, 2007) . In experimental and human cirrhosis, fibrosis appears to be the result not only of excessive ECM synthesis but also of reduced degradation, which is caused by the up-regulation of TIMPs inactivating the concurrently secreted MMPs (Iredale, 2007) . According to these mechanisms, the untreated fibrotic rats in our experiments presented a marked induction of Col1α2 gene expression as well as a significant up-regulation of the MMPs. This can be explained as a compensatory mechanism designed to eliminate the excess of scar tissue. However, the concomitant TIMP induction TIMPs rather than by their absolute levels (Iredale, 2007) . Accordingly, several investigations have proposed that the inhibitory activity of TIMPs is the leading regulator of the remodeling process (Iredale, 2007; Arthur, 2000) . In our study, treatment with both AM1241 and F13A was associated with a significant increase in the MMPs/TIMPS ratio in agreement with the inhibition of fibrosis progression. This altered balance was due to TIMP1 inhibition rather than to a further activation of MMPs. This further supports the concept that TIMPs activity is a major regulator of the ECM degradation pattern in the injured liver by controlling the activity of the secreted MMPs.
Tissue repair is a homeostatic response toward tissue injury in which multiple and complex proinflammatory, proangiogenic and profibrogenic processes are activated. In the liver, maintenance of tissue aggression results in the perpetuation of these phenomena, the wound healing response progressively leading to advanced fibrosis and eventually cirrhosis. Breaking this vicious circle is a major challenge to stop fibrosis in patients with liver disease. In the current investigation we have shown that stimulating CB2 receptors or blocking the activity of the hepatic apelin system is able to attenuate collagen deposition in CCl 4 -treated rats through common mechanisms. In fact, in spite of the marked differences in the signaling pathways driving endocannabinoids and AP antifibrogenic effects, both inhibit PDGFRβ expression and alter MMPs/TIMPs balance by decreasing TIMP1 messenger and protein abundance. These results, therefore, point to PDGF signaling and TIMP1 activity as major targets for future antifibrotic therapies.
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